Related Articles
Non-small cell neuroendocrine carcinoma of the ovary in a BRCA2-germline mutation carrier: A case report and brief review of the literature
Metastatic breast cancer with double heterozygosity for the <em>BRCA1 </em>and <em>BRCA2</em> genes responding to olaparib: A case report
Efficacy and safety of different angiogenesis inhibitors combined with PARP inhibitors in the treatment of ovarian cancer: A systematic review and meta‑analysis
Exposure to escalating olaparib does not induce acquired resistance to PARPi and to other chemotherapeutic compounds in ovarian cancer cell lines
Long‑term response to Olaparib in carcinomatous meningitis of a BRCA2 mutated ovarian cancer: A case report